GlassScriptPhysician profile
Robert H Dudley
NPI 1619973328
$1,053.65
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.76 · 2021: $134 · 2022: $410 · 2023: $270 · 2024: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $140.12 | 2024 | |
| Pfizer INC. | $106.54 | 2019-2022 | |
| Novo Nordisk INC | $102.99 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $94.24 | 2023 | Spravato |
| Abbvie INC. | $82.03 | 2022 | |
| Supernus Pharmaceuticals, INC. | $75.47 | 2022-2023 | Qelbree |
| Amarin Pharma, INC. | $64.58 | 2021 | |
| Glaxosmithkline, LLC. | $62.87 | 2019-2023 | Shingrix |
| Abbott Laboratories | $45.32 | 2022-2023 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $38.22 | 2022 | |
| Currax Pharmaceuticals LLC | $26.97 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.38 | 2022 | |
| Astellas Pharma US INC | $22.96 | 2022 | |
| Alkermes, INC. | $22.48 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $22.00 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $21.82 | 2022 | |
| Hologic Sales and Service, LLC | $19.54 | 2023 | Aptima, Thinprep 2000 Processor |
| Boston Scientific Corporation | $16.79 | 2023 | Watchman Flx |
| Jazz Pharmaceuticals INC. | $15.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Orexo US, INC. | $13.22 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.95 | 2022 | |
| Qol Medical, LLC | $7.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dudley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.